img02

Press Releases

July 17, 2015

Fortress Biotech Subsidiary, Escala Therapeutics, Acquires NIH License and CRADAs Relating to the Development of N-acetyl-D-mannosamine (ManNAc) for Rare Genetic Disorders

July 17th, 2015

ManNAc to be Studied as Potential Treatment of Hereditary Inclusion Body Myopathy (HIBM) and Various Nephropathies Associated with Hyposialylation New York, NY – July 17, 2015 – Fortress Biotech, Inc. (NASDAQ: FBIO) announced that its subsidiary, Altamira Bio, acquired from New Zealand Pharmaceuticals Ltd (NZP), a license from the National Institutes of Health (NIH) and […]

Escala Therapeutics